4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclobutyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclobutyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester
• 英文别名: cis-4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclobutyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester；propan-2-yl 4-[[3,5-bis(trifluoromethyl)phenyl]methyl-methoxycarbonylamino]-2-cyclobutyl-6-(trifluoromethyl)-3,4-dihydro-2H-quinoline-1-carboxylate
• 化学式: C₂₉H₂₉F₉N₂O₄
• 分子量: 640.546
• InChiKey: RRPVNLZHOJXQAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.8
• 重原子数：
  44
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  59.1
• 氢给体数：
  0
• 氢受体数：
  13

文献信息

• 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
  申请人：Pfizer Inc.

  公开号：US20040092550A1

  公开（公告）日：2004-05-13

  Cholesteryl ster transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain oth r plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

  胆固醇酯转移蛋白抑制剂，含有这种抑制剂的制药组合物以及使用这种抑制剂来提高某些血浆脂质水平，包括高密度脂蛋白胆固醇，降低某些其他血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，并相应地治疗由HDL胆固醇水平低和/或LDL胆固醇和甘油三酯水平高加重的疾病，如动脉粥样硬化和某些哺乳动物，包括人类的心血管疾病。
• 4-CARBOXYAMINO-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS
  申请人：Pfizer Products Inc.

  公开号：EP1114031B1

  公开（公告）日：2005-06-15
• PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS
  申请人：Pfizer Products Inc.

  公开号：EP1305007A2

  公开（公告）日：2003-05-02
• PHARMACEUTICAL COMPOSITIONS COMPRISING LOW-SOLUBILITY AND/OR ACID-SENSITIVE DRUGS AND NEUTRALIZED ACIDIC POLYMERS
  申请人：Pfizer Products Inc.

  公开号：EP1399190A1

  公开（公告）日：2004-03-24
• PHARMACEUTICAL COMPOSITIONS CONTAINING A SOLID DISPERSION OF A POORLY-SOLUBLE DRUG IN A MATRIX AND A SOLUBILITY-ENHANCING POLYMER
  申请人：Pfizer Products Inc.

  公开号：EP1401503A1

  公开（公告）日：2004-03-31